title: No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years.
abstract: The appropriate dose of progestogen during long-cycle hormone replacement is still under debate. We present preliminary two-year results from an open five-year clinical trial of 132 postmenopausal women. All subjects had long-cycle HRT consisting of 70 days 2 mg oestradiol valerate (E(2)V), followed by 14 days 2 mg E(2)V plus 20 mg medroxyprogesterone acetate, and a seven-day hormone-free period. No endometrial samples with hyperplasia or indicative of malignancy were found at 24 months.
authors.affiliation: University Central Hospital, Turku, Finland.
authors.forename: Risto
authors.initials: R
authors.lastname: Erkkola
authors.forename: Ulpu
authors.initials: U
authors.lastname: Kumento
authors.forename: Sirpa
authors.initials: S
authors.lastname: Lehmuskoski
authors.forename: Leena
authors.initials: L
authors.lastname: Mattila
authors.forename: Mika
authors.initials: M
authors.lastname: Mustonen